MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329840 | Name: Disopyramide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Disopyramide is an antiarrhythmic medication used in the treatment of ventricular tachycardia. It is a sodium channel blocker and therefore classified as a Class 1a anti-arrhythmic agent. Disopyramide has a negative inotropic effect on the ventricular myocardium, significantly decreasing the contractility. Disopyramide also has an anticholinergic effect on the heart which accounts for many adverse side effects. Disopyramide is available in both oral and intravenous forms, and has a low degree of toxicity.

Chemical Structure

Disopyramide
Disopyramide
CAS#3737-09-5 (free base)

Theoretical Analysis

MedKoo Cat#: 329840

Name: Disopyramide

CAS#: 3737-09-5 (free base)

Chemical Formula: C21H29N3O

Exact Mass: 339.2311

Molecular Weight: 339.48

Elemental Analysis: C, 74.30; H, 8.61; N, 12.38; O, 4.71

Price and Availability

Size Price Availability Quantity
1g USD 250.00 2 weeks
2g USD 400.00 2 Weeks
5g USD 750.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
3737-09-5 (free base) 22059-60-5 (phosphate) 54687-36-4 (HCl)
Synonym
SC 7031; SC-7031; Searle 703; H 3292; Ritmodan; Dicorantil. (±)-Disopyramide; trade names Norpace and Rythmodan.
IUPAC/Chemical Name
2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-
InChi Key
UVTNFZQICZKOEM-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
SMILES Code
O=C(N)C(C1=CC=CC=C1)(CCN(C(C)C)C(C)C)C2=NC=CC=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Disopyramide inhibits HERG encoded potassium channels.
In vitro activity:
The association rate constant of disopyramide for the normal and modified channel at -20 mV was similar, approximately 10 x 10(6)/M/sec. During exposure to disopyramide, changes in open and closed times and in open channel noise at -80 and -100 mV are consistent with fast block and unblocking events at these potentials. Reference: J Membr Biol. 1993 Nov;136(2):199-214. https://pubmed.ncbi.nlm.nih.gov/8107074/
In vivo activity:
This study examined the effects of DISO (disopyramide) on potassium channels encoded by HERG, as this K channel type has been implicated in both congenital and acquired long-QT syndromes (LQTS). Chinese hamster ovary cells were transiently transfected with HERG cDNA for subsequent whole cell patch clamp recording. HERG tail currents recorded at -40 mV following test pulses to +30 mV were inhibited in a dose-dependent fashion by DISO concentrations within the clinical range (IC50 = 7.23 +/- 0.72 microM; mean +/- SEM). Reference: Biochem Biophys Res Commun. 2001 Feb 9;280(5):1243-50. https://pubmed.ncbi.nlm.nih.gov/11162661/
Solvent mg/mL mM
Solubility
DMSO 158.5 466.89
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 339.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Grant AO, Wendt DJ, Zilberter Y, Starmer CF. Kinetics of interaction of disopyramide with the cardiac sodium channel: fast dissociation from open channels at normal rest potentials. J Membr Biol. 1993 Nov;136(2):199-214. doi: 10.1007/BF02505764. PMID: 8107074. 2. Jones SV, Marshall IG. Non-competitive effects of disopyramide at the neuromuscular junction: evidence for endplate ion channel block. Br J Anaesth. 1987 Jun;59(6):776-83. doi: 10.1093/bja/59.6.776. PMID: 2440467. 3. Paul AA, Witchel HJ, Hancox JC. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide. Biochem Biophys Res Commun. 2001 Feb 9;280(5):1243-50. doi: 10.1006/bbrc.2001.4269. PMID: 11162661. 4. Elliott RA, Hudman D, Terry T, Sandhu D, Norman RI. Inhibition of isolated rat and human detrusor muscle contraction by disopyramide. J Auton Pharmacol. 2000 Aug;20(4):229-36. doi: 10.1046/j.1365-2680.2000.00185.x. PMID: 11260361.
In vitro protocol:
1. Grant AO, Wendt DJ, Zilberter Y, Starmer CF. Kinetics of interaction of disopyramide with the cardiac sodium channel: fast dissociation from open channels at normal rest potentials. J Membr Biol. 1993 Nov;136(2):199-214. doi: 10.1007/BF02505764. PMID: 8107074. 2. Jones SV, Marshall IG. Non-competitive effects of disopyramide at the neuromuscular junction: evidence for endplate ion channel block. Br J Anaesth. 1987 Jun;59(6):776-83. doi: 10.1093/bja/59.6.776. PMID: 2440467.
In vivo protocol:
1. Paul AA, Witchel HJ, Hancox JC. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide. Biochem Biophys Res Commun. 2001 Feb 9;280(5):1243-50. doi: 10.1006/bbrc.2001.4269. PMID: 11162661. 2. Elliott RA, Hudman D, Terry T, Sandhu D, Norman RI. Inhibition of isolated rat and human detrusor muscle contraction by disopyramide. J Auton Pharmacol. 2000 Aug;20(4):229-36. doi: 10.1046/j.1365-2680.2000.00185.x. PMID: 11260361.
1: Verlinden NJ, Coons JC. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug. Pharmacotherapy. 2015 Dec;35(12):1164-72. doi: 10.1002/phar.1664. Review. PubMed PMID: 26684556. 2: Isabelle le BL, Clarot F, Vaz E, Goullé JP, Proust B. Disopyramide and mianserin intoxication: a unique fatal case--review of the literature. J Forensic Sci. 2014 May;59(3):850-3. doi: 10.1111/1556-4029.12392. Epub 2014 Feb 6. Review. PubMed PMID: 24502246. 3: Sherrid MV, Arabadjian M. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2012 May-Jun;54(6):483-92. doi: 10.1016/j.pcad.2012.04.003. Review. PubMed PMID: 22687589. 4: Abe M, Maruyama T, Fujii Y, Kitai M, Okada K, Matsumoto K, Soma M. Disopyramide-induced hypoglycemia in a non-diabetic hemodialysis patient: a case report and review of the literature. Clin Nephrol. 2011 Nov;76(5):401-6. Review. PubMed PMID: 22000561. 5: Hamada M, Ikeda S, Shigematsu Y. Advances in medical treatment of hypertrophic cardiomyopathy. J Cardiol. 2014 Jul;64(1):1-10. doi: 10.1016/j.jjcc.2014.02.022. Epub 2014 Apr 13. Review. Erratum in: J Cardiol. 2014 Oct;64(4):330. PubMed PMID: 24735741. 6: Sherrid MV. Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice. Curr Cardiol Rev. 2016;12(1):52-65. Review. PubMed PMID: 26818487; PubMed Central PMCID: PMC4807719. 7: Siddoway LA, Woosley RL. Clinical pharmacokinetics of disopyramide. Clin Pharmacokinet. 1986 May-Jun;11(3):214-22. Review. PubMed PMID: 3524956. 8: Brogden RN, Todd PA. Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias. Drugs. 1987 Aug;34(2):151-87. Review. PubMed PMID: 3304965. 9: Morady F, Scheinman MM, Desai J. Disopyramide. Ann Intern Med. 1982 Mar;96(3):337-43. Review. PubMed PMID: 7036817. 10: Heel RC, Brogden RN, Speight TM, Avery GS. Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias. Drugs. 1978 May;15(5):331-68. Review. PubMed PMID: 350555. 11: Granowitz EV, Tabor KJ, Kirchhoffer JB. Potentially fatal interaction between azithromycin and disopyramide. Pacing Clin Electrophysiol. 2000 Sep;23(9):1433-5. Review. PubMed PMID: 11025903. 12: Taylor EH, Pappas AA. Disopyramide: clinical indications, pharmacokinetics and laboratory assessment. Ann Clin Lab Sci. 1986 Jul-Aug;16(4):289-95. Review. PubMed PMID: 2427003. 13: Kim SY, Benowitz NL. Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide. Drug Saf. 1990 Nov-Dec;5(6):393-420. Review. PubMed PMID: 2285495. 14: Karim A, Nissen C, Azarnoff DL. Clinical pharmacokinetics of disopyramide. J Pharmacokinet Biopharm. 1982 Oct;10(5):465-94. Review. PubMed PMID: 6762414. 15: Vaughan Williams EM. Disopyramide. Ann N Y Acad Sci. 1984;432:189-200. Review. PubMed PMID: 6395761. 16: Sathyavagiswaran L. Fatal disopyramide intoxication from suicidal/accidental overdose. J Forensic Sci. 1987 Nov;32(6):1813-8. Review. PubMed PMID: 3323413. 17: Barnay C. [Effects of disopyramide on normal and pathological atrioventricular conduction]. Ann Cardiol Angeiol (Paris). 1992 Oct;41(8):449-53. Review. French. PubMed PMID: 1298185. 18: Di Bianco R, Gottdiener JS, Singh SN, Fletcher RD. A review of the effects of disopyramide phosphate on left ventricular function and the peripheral circulation. Angiology. 1987 Feb;38(2 Pt 2):174-83. Review. PubMed PMID: 3103491. 19: Wilson RR, Wallace AG. Disopyramide: six years' experience. Angiology. 1983 Jun;34(6):367-74. Review. PubMed PMID: 6346959. 20: Ankier SI, Carmichael DJ, Kidner PH. Disopyramide--a review. Scott Med J. 1977 Oct;22(4):314-9. Review. PubMed PMID: 337485.